Viewing Study NCT03013933


Ignite Creation Date: 2025-12-25 @ 3:00 AM
Ignite Modification Date: 2026-02-27 @ 4:32 PM
Study NCT ID: NCT03013933
Status: COMPLETED
Last Update Posted: 2024-02-22
First Post: 2017-01-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Sponsor: City of Hope Medical Center
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Recurrent Hodgkin Lymphoma View
None Refractory Hodgkin Lymphoma View
Keywords: